Novo’s Victoza beats Bydureon in head-to-head trial
March 4, 2011Research and Development, Sales and Marketing Alkermes, Amylin, Byureon, Victoza, diabetes, exenatide, lilly, type II diabetes
Bydureon has been outperformed by rival Victoza in a head-to-trial, decimating shares in its co-developer Amylin and Alkermes, the company …
Onglyza expands European licence
March 4, 2011Sales and Marketing AZ, AstraZeneca, BMS, Bristol-Myers Squibb, Onglyza, diabetes, renal impairment, saxagliptin, type II diabetes
European regulators have approved a licence extension for diabetes treatment Onglyza, making it the first drug in its class that …
First idiopathic pulmonary fibrosis drug approved
March 4, 2011Sales and Marketing Esbriet, IPF, InterMune, Orphan Drugs, idiopathic pulmonary fibrosis, orphan drug
The first ever treatment for the potentially fatal lung disease idiopathic pulmonary fibrosis (IPF) has been approved in the EU. …
Digital Pharma: online campaign directory updated
March 4, 2011Medical Communications, Sales and Marketing Digital Pharma blog, Novartis, Pfizer, Sanofi-Aventis, VTE, diabetes, erectile dysfunction, pharmacist educaiton, venous thromboembolism, viagra
The latest update to the Digital Pharma links directory covers its online campaigns section and includes a pharmacist networking portal …
Market forces won’t produce needed restructure, warns King’s Fund
March 4, 2011GP consortia, Health and Social Care Bill, Kings Fund, NHS, NHS Commissioning Board, NHS reforms, foundation trusts, hospital trusts, king's fund
Greater competition in the NHS is unlikely to bring about the restructuring needed in hospital services, according to The King’s …
Former McCann MD launches patient-focused agency
March 4, 2011Medical Communications Craig Mills, Frontera, healthcare communications agency, medical communications
An agency specialising in professional, consumer and public health has been launched by a former managing director at McCann Healthcare. …
Medical bodies back ABPI Code changes
March 4, 2011Medical Communications ABPI, ABPI Code of Practice, Code of Practice, GMC, INFORCE, Nottingham, Royal College of Physicians, industry relations, trust
Leading medical organisations have signed a joint declaration backing the forthcoming changes to UK pharma’s self-regulatory Code of Practice. In …
NICE rejects Lucentis for diabetic oedema
March 4, 2011Sales and Marketing Lucentis, NICE, Novartis, VEGF, Vascular Endothelial Growth Factor, diabetic oedema, raibizumab
NICE’s draft guidance has not recommended Lucentis for diabetic oedema after ‘faulty analysis’ from manufacturer Novartis was found not to …
Digital Pharma: European doctors’ communities collaborate
March 3, 2011Medical Communications, Sales and Marketing Coliquio, Digital Pharma blog, Doctors.net.uk, online doctors communities
Two of Europe’s leading medical professional communities have signed a strategic alliance that will see them collaborate on multi-market digital …
Jim McDermott to lead Quintiles Market Intelligence
March 3, 2011Sales and Marketing Jim McDermott, Quintiles, appointment, sales and marketing
Quintiles has appointed Jim McDermott as managing director of the Market Intelligence practice within its Consulting group. The practice provides …
Universities to ‘pick up pharma’s R&D mantle’ after Pfizer closure
March 3, 2011Research and Development Kent, Pfizer, Sandwich, Science and Technology Select Committee, UK research, UK science, job cuts
Science in the UK will have to focus on contractually-based research in the future as pharma’s R&D presence in the …
GSK to reimburse tuition fees for UK trainees
March 3, 2011Business Services, Research and Development, Sales and Marketing GSK, GlaxoSmithKline, UK science, careers, graduate, graduate recruitment
GlaxoSmithKline is set to reimburse UK university tuition fees paid by its trainees from 2012. Each year, GSK recruits between …
Forest’s COPD drug approved in US
March 3, 2011Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast
Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …
RNA interference – still the great white hope?
March 3, 2011Manufacturing and Production, Research and Development RNA interference, rnai
The emerging field of RNA interference – also known as ‘gene silencing’ – is one of the most promising in …
NHS competition plans provide focus for dissent
March 3, 2011Health and Social Care Bill, NHS, NHS reforms
Confusion and controversy surround the government plans to introduce greater levels of competition into the NHS, with many stakeholder groups …
FDA knocks back Merck KGaA’s oral MS drug
March 2, 2011Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs
US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …
UCB teams up with Harvard for CNS research
March 2, 2011Research and Development CNS, Harvard, UCB, academia, academic research, immunology
UCB has signed a new research collaboration with Harvard University that will focus on central nervous system and immunology therapies. …
Boehringer’s Kay O’Hagan moves to Brecon
March 2, 2011Manufacturing and Production, Research and Development Brecon, Kay O'Hagan, appointment, manufacturing and production, research and development
Kay O’Hagan has joined commercial packaging and clinical trials supply services company Brecon Pharmaceuticals as director of quality assurance and …
Avastin’s breast cancer use to continue in Europe
March 2, 2011Sales and Marketing CHMP, Cancer, European Commission, Roche, avastin, bevacizumab, breast cancer, docetaxel, paclitaxel
Roche’s Avastin will remain on the market as a treatment for breast cancer, but only in combination with paclitaxel, the …
GlaxoSmithKline seeks alliances with ‘academic superstars’
March 2, 2011Research and Development GSK, GlaxoSmithKline, Pentraxin Therapeutics, academia, al Free and University College Medical School, universities
GlaxoSmithKline has unveiled a partnership with a ‘superstar academic’, as part of a new strategy which it believes will help …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
